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for ErbB2-induced mammary tumorigenesis
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Abstract
Background: Altered tumor cell metabolism is an emerging hallmark of cancer; however, the precise role for
glucose in tumor initiation is not known. GLUT1 (SLC2A1) is expressed in breast cancer cells and is likely responsible
for avid glucose uptake observed in established tumors. We have shown that GLUT1 was necessary for xenograft
tumor formation from primary mammary cells transformed with the polyomavirus middle-T antigen but that it was
not necessary for growth after tumors had formed in vivo, suggesting a differential requirement for glucose
depending on the stage of tumorigenesis.
Methods: To determine whether GLUT1 is required early during mammary tumorigenesis, we crossed MMTV-NIC
mice, which express activated HER2/NEU/ERBB2 and Cre recombinase, to Slc2a1Flox/Flox (GLUT1Flox/Flox) mice to
generate NIC-GLUT1+/+, NIC-GLUT1Flox/+, and NIC-GLUT1Flox/Flox mice. In addition, we evaluated effects of glucose
restriction or GLUT1 inhibition on transformation in MCF10A-ERBB2 breast epithelial cells in three-dimensional
culture. Finally, we utilized global gene expression profiling data of primary human breast tumors to determine the
relationship between SLC2A1 and stage of tumorigenesis.
Results: All of the NIC-GLUT1+/+ mice developed tumors in less than 200 days. In contrast, only 1 NIC-GLUT1Flox/Flox
mouse and 1 NIC-GLUT1Flox/+ mouse developed mammary tumors, even after 18 months. Mammary gland
development was not disrupted in NIC mice lacking GLUT1; however, epithelial content of mature glands was
reduced compared to NIC-GLUT1Flox/+ mice. In MCF10A-ERBB2 cells, glucose restriction or GLUT1 inhibition blocked
transformation induced by activated ERBB2 through reduced cell proliferation. In human breast cancers, SLC2A1 was
higher in ductal carcinoma in situ compared to the normal breast, but lower in invasive versus in situ lesions,
suggesting the requirement for GLUT1 decreases as tumors progress.
Conclusions: This study demonstrates a strict requirement for GLUT1 in the early stages of mammary
tumorigenesis in vitro and in vivo. While metabolic adaptation has emerged as a hallmark of cancer, our data
indicate that early tumor cells rely heavily on glucose and highlight the potential for glucose restriction as a breast
cancer preventive strategy.
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Background
It is well established that cancer cells require abundant
glucose, not only to meet the energy demands of rapidly
proliferating cells, but also to provide a carbon source
for building blocks that generate nucleotides, proteins,
cell membrane lipids, and reducing power in the form of
NADPH. Glucose utilization by cancer cells has been
studied for decades since Warburg’s initial observations
in 1924 that tumors perform glycolysis even in the pres-
ence of abundant oxygen [1, 2]. Initially, it was thought
that cancer cell mitochondria were dysfunctional and
that the cells relied on glucose to provide ATP through
glycolysis. Now we know that cancer cell mitochondria
are capable of providing sufficient ATP through oxida-
tive phosphorylation, and it has been suggested that the
majority of glucose carbons are shunted from glycolysis
to adjacent pathways for the purpose of generating
amino acids, nucleotides, and fatty acids [3]. The height-
ened cancer cell demand for glucose has been exploited
in diagnostic procedures, which rely on positron emis-
sion tomography (PET) imaging of tumor tissues that
have taken up 18F-fluoro-2-deoxyglucose (FDG) [4, 5].
PET scanning has been clinically useful for detecting
recurring lesions as well as emergence of metastatic
lesions, and increased FDG uptake has been associated
with higher grade [6, 7], poorly differentiated tumors [8, 9],
and high proliferation rates [8, 10] in breast cancer.
Glucose enters cells through various transporters
including the GLUT family of facilitative transporters,
the sodium/glucose co-transporters, and the recently
discovered SWEET family [11]; however, only the role of
the GLUT family has been extensively studied in cancer
cells. There are 14 GLUT proteins in the human and 12
in the mouse [12]. GLUT1, encoded by SLC2A1, is the
predominant transporter overexpressed in tumors,
including hepatic, pancreatic, esophageal, brain, renal,
lung, cutaneous, colorectal, endometrial, ovarian,
cervical, and breast, as well as head and neck tumors
(reviewed in [13]). In addition to GLUT1, expression of
GLUTs 2–5 has been observed in breast tumors, but
levels of these transporters are variable (reviewed in
[13]). In breast cancer, the extent of tumors positive for
GLUT1 by immunohistochemistry varies from 42% to
greater than 90% [7, 10, 14–16]. Although it is not clear
when GLUT1 expression is increased during tumorigen-
esis, Alo et al. observed that 36% of typical/atypical
hyperplastic breast tissue expressed GLUT1 and normal
adjacent tissues were positive in 31% of cases, suggesting
that overexpression of GLUT1 may occur early in the
transformation process [14]. Pinheiro et al. evaluated
GLUT1 levels in 124 cases of breast cancer that were
stratified by subtype, receptor status, and other molecu-
lar markers, and demonstrated that GLUT1 was associ-
ated with increased tumor size, higher tumor grade,
higher rates of proliferation, and was predominately
expressed in the basal subtype [17]. GLUT1 expression
was also associated with increased expression of
carbonic anhydrase, perhaps reflecting the altered
metabolism in these tumors [17]. It is unclear whether
GLUT1 levels correlate with FDG uptake, although PET
scanning remains clinically important in the manage-
ment of breast cancer [8, 18].
GLUT2 and GLUT3 [19] have been detected in
approximately 30% of invasive breast cancer tissues, and
GLUT4 appears to be expressed in even fewer cases [19,
20]. GLUT12 was cloned from MCF7 cells [21] and was
found to be expressed at relatively higher levels in mam-
mary tumors compared to surrounding normal epithelial
cells [22]. There are conflicting reports of GLUT5 levels
in breast cancer, with studies showing that GLUT5 is
[23] and is not [24] overexpressed in primary breast
cancer samples and cell lines.
Expression of GLUT1 is induced by hypoxia [25, 26],
c-myc [27], and by Akt1 [28]. A complex of hypoxia
inducible factor 1α (HIF1α) and aryl-hydrocarbon recep-
tor nuclear translocator (ARNT) has been shown to bind
to the GLUT1 promoter and upregulate its expression
[25]. In addition, estrogen, acting through the estrogen
receptor, has also been shown to induce GLUT1 levels
in breast cancer cells [29]. The majority of triple-
negative breast cancers have high levels of GLUT1 as
measured in tissue microarrays [30].
We previously showed that GLUT1 was the most
abundantly expressed glucose transporter in cell lines
derived from ERBB2/NEU-induced mouse mammary
tumors and that shRNA-mediated reduction of
GLUT1 in mouse mammary tumor cell lines de-
creased glucose uptake and proliferation without al-
tering ATP levels [31]. When these cells were grown
as xenograft tumors, the growth rate of GLUT1
knockdown cells was approximately half of the con-
trols, suggesting that GLUT1 and potentially glucose
uptake were not critical to support the growth of tu-
mors once they were established. These studies were
extended using mammary epithelial cells isolated
from mice bearing floxed alleles of Slc2a1 (referred
to as GLUT1F/F) and transformed with polyomavirus
middle-T antigen (PyMT) in vitro. Cre-mediated
Slc2a1 excision completely prevented tumor forma-
tion when cells were grown as orthotopic xenografts.
When Slc2a1 was excised after the cells had grown
as tumors in vivo (i.e., when cells were cultured
from control tumors and then treated with Cre
recombinase), a decrease in tumor growth rates and
glucose uptake was observed in the absence of
GLUT1, but tumors formed. These studies suggested
that GLUT1 expression and glucose uptake are early,
obligate events for mammary tumor formation.
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In the current study, we crossed the MMTV-NIC
(mouse mammary tumor virus promoter-Neu-IRES-Cre)
transgenic mouse line to GLUT1F/F mice [31]. Here, we
show that loss of one or both alleles of Slc2a1 from mam-
mary epithelial cells expressing the active Neu oncogene
prevented tumor formation. In addition, blocking GLUT1
or restricting available glucose led to decreased cell prolif-
eration and suppressed features of transformation in
MCF10A cells expressing a conditionally active human
epidermal growth factor receptor 2 (HER2/NEU/ERBB2)
construct (MCF10A-ERBB2). These studies confirm that
restricting glucose uptake inhibits mammary tumorigen-
esis in ERBB2-induced models and support the develop-




Transgenic MMTV-NIC (Neu-IRES-Cre) mice were
kindly provided by Dr. William Muller (McGill
University, Montreal, Canada) and have been described
previously [32]. GLUT1Flox/Flox (GLUT1F/F) mice were
generated by E. Dale Abel (University of Iowa, Iowa City,
IA, USA) as described previously [31], and were back-
crossed to the FVB genetic background using a speed
congenic approach. All mice used in this study
contained greater than 90% FVB alleles as determined
by marker analysis (data not shown). Mice were housed
in the Center for Comparative Medicine, with ad libitum
access to food and water on a standard 12-h light/dark
cycle. MMTV-NIC males were bred to GLUT1F/F
females, and then NIC-GLUTF/+ males were bred to
GLUT1F/+ females to generate NIC-GLUT1+/+, NIC-
GLUT1F/+, and NIC-GLUT1F/F progeny. Female mice
were palpated weekly for mammary tumors beginning at
8 weeks of age. The age of the mouse upon first palpable
mammary tumor was recorded for Kaplan-Meier
analysis. Tumor studies were carried out to 18 months.
All animal studies were conducted in accordance with
protocols approved by the Institutional Animal Use and
Care Committee of the University of Colorado, Denver,
USA.
Mammary whole mounts
Mammary whole mounts were performed as previously
described using standard carmine-alum staining proto-
cols [33].
Antibodies and immunohistochemistry
Tissues were fixed in 10% neutral-buffered formalin, and
processed and embedded according to standard
histologic protocols. Five-micron sections were stained
with hematoxylin and eosin (H&E) or used for immuno-
histochemical analysis. The GLUT1 antibody has been
described previously [31]. Anti-Cre recombinase anti-
body was from Thermo Scientific, anti-Ki67 antibody
was obtained from Dako, and anti-BrdU antibody was
from Abcam. Cre recombinase and Ki67 were quantified
by counting the number of positive cells out of the total
number of mammary epithelial cells in one full, repre-
sentative mammary gland section per mouse. BrdU
staining was quantified by counting the number of
positive cells out of the total cells per acinar structure in
3–4 paraffin-embedded sections per treatment, cut every
50 μm. GLUT1 and tumor area were quantified using
the Aperio Digital Pathology system (Leica Biosystems).
Cell culture
MCF10A-ERBB2 cells were provided by Dr. Senthil
Muthuswamy (Harvard Medical School) and cultured as
described [34]. Cells were authenticated by short tandem
repeat (STR) analysis within 6 months of performing
experiments. Cells were mycoplasma negative as deter-
mined by the MycoAlert Mycoplasma Detection Kit
(Lonza). Matrigel was obtained from BD Biosciences and
the ERBB2 construct was activated by addition of the BB
homodimerizer (BD Biosciences) at a concentration of
500 nM. WZB117 was purchased from Sigma-Aldrich.
The size of MCF10A-ERBB2 acinar structures under
different culture conditions was determined at indicated
times by capturing digital images of the colonies using a
4× objective on a Nikon Eclipse Ti microscope. Volumes
were calculated from measured diameters and NIS
Elements AR software. Matrigel-embedded acinar struc-
tures were incubated with 0.25 mg/mL BrdU (Sigma
Aldrich) for 1 h, fixed in 4% paraformaldehyde, embed-
ded in Histogel (Thermo Scientific), and embedded in
paraffin for immunohistochemical analysis.
Flow cytometry
All females were in estrus at sacrifice, as determined by
examination of cells from vaginal lavage. Whole inguinal
(#4) mammary glands were dissected and digested at
37 °C for 4 h in 1 mg/mL collagenase B (Roche) and
0.5 mg/mL hyaluronidase (Sigma Aldrich) with gentle
shaking. Dissociated cells were washed and filtered
through a 50-μm cell strainer before incubating with
antibodies. All antibodies for flow cytometry were pur-
chased from BioLegend. Antibodies to CD31, CD45, and
TER119 were conjugated to Pacific Blue. Additional
antibodies used were Alexa-fluor 488 anti-CD24, APC
anti-CD29, and PE anti-CD61. Samples were analyzed
on a Galios (Beckman Coulter). Analysis was performed
with Kaluza Analysis Software (Beckman Coulter).
RNA isolation and quantitative PCR analysis
RNA was isolated from acinar structures using Qiazol
(Qiagen). One microgram of total RNA was reverse
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transcribed using the Verso cDNA synthesis kit (Thermo
Scientific). Quantitative polymerase chain reaction (PCR)
was performed as previously described [35], using Taqman
primers and probe to SLC2A1 (Life Technologies).
Human data analysis
The gene expression data from normal breast, ductal
carcinoma in situ (DCIS), and invasive ductal carcinoma
(IDC) samples are publicly available in dataset GSE59246.
Raw data and annotation files from this dataset were
downloaded and samples were sorted by tissue type. Log2
transformed expression of SLC2A1 was plotted based on
tissue type and analyzed using unpaired t tests to compare
DCIS to normal breast and IDC to DCIS.
Statistical analyses
Tumor latencies are shown as Kaplan-Meier survival
curves. Because only one animal in the NIC-GLUT1F/+
and NIC-GLUT1F/F groups developed a tumor, we were
unable to define a median survival time for these groups
and we were insufficiently powered to perform robust
statistical analyses. For all analyses, we used D’Agostino
and Pearson omnibus normality test, and then unpaired t
tests or non-parametric tests depending on whether data
were normally distributed or not. When variances were
found to be unequal, this was accounted for in the t test
using a Welch’s correction. If sample sizes were too small
to assess normality, we performed non-parametric tests.
The level of significance for all tests was set at 0.05.
Results
GLUT1 loss prevents mammary tumor formation without
disrupting normal cell growth
We previously showed that eliminating GLUT1 from
PyMT-transformed primary mouse mammary epithelial
cells prior to orthotopic injection prevented tumor
formation when cells were implanted into immune-
compromised mice [31]. In contrast, when GLUT1 was
deleted from cells that had previously grown as xeno-
graft tumors in vivo, glucose uptake and lactate produc-
tion were reduced; however, these cells lacking GLUT1
formed slow-growing tumors [31]. Based on these stud-
ies, we hypothesized that glucose uptake, mediated by
GLUT1, is critical for the initial steps of mammary
tumorigenesis and the emergence of a mammary tumor.
To test this hypothesis, we crossed MMTV-NIC mice to
GLUT1Flox/Flox (GLUT1F/F) mice, and monitored mam-
mary tumor formation in NIC-GLUT1+/+, NIC-
GLUT1F/+, and NIC-GLUT1F/F progeny. NIC-GLUT1+/+
mice developed mammary tumors with a median latency
of 162 days and all mice formed tumors by 200 days
(Fig. 1a), consistent with previous reports from this
model [32]. In contrast, tumor development was delayed
in NIC-GLUT1F/+ and NIC-GLUT1F/F mice. Only one
NIC-GLUT1F/+ and one NIC-GLUT1F/F mouse developed
tumors, with latencies of 189 and 143 days, respectively
(Fig. 1a).
To determine whether GLUT1 excision interfered with
the development of the mammary ductal tree, we evalu-
ated epithelial structures in whole mounted mammary
glands and H&E sections from mature (4–6 months of
age), nulliparous female mice. In both NIC-GLUT1F/+
and NIC-GLUT1F/F mice, we observed fully developed
mammary glands. NIC-GLUT1F/+ mice appeared to have
increased epithelial content that appeared like alveolar
buds along ducts, which could also represent hyperpla-
sia, but no tumors were observed (Fig. 1b and d). In
NIC-GLUT1F/F mice, we observed lower epithelial
content compared to NIC-GLUTF/+, and no tumors
(Fig. 1c and e). In mammary gland sections, we found
that NIC-GLUTF/+ mice had areas of dense epithelium
(Fig. 1f ), consistent with what we observed in whole
mounts (Fig. 1b and d), but this was not seen in NIC-
GLUT1F/F glands (Fig. 1g). In fact, NIC-GLUT1F/F
glands more closely resembled those of wild-type FVB
mice (Fig. 1h) than those of NIC-GLUT1F/+ (Fig. 1f ) or
NIC-GLUT1+/+ (Fig. 1i) mice. Thus, Cre-mediated exci-
sion of Glut1 in the adult mouse mammary gland does
not appear to disrupt ductal elongation or branching.
The NIC transgene expresses both Neu and Cre
recombinase; therefore, we used Cre expression as an in-
dicator of transgene expression. Strong, nuclear Cre ex-
pression was detected in all tumors examined from the
NIC-GLUT1+/+ mice (Fig. 2a), and these tumors also
expressed GLUT1 (Fig. 2b). Both Cre recombinase and
GLUT1 were detected in tumors from the NIC-
GLUT1F/+ mouse (Fig. 2d and e). In the tumors from
the NIC-GLUT1F/F mouse, we detected Cre recombin-
ase, but not epithelial expression of GLUT1 (Fig. 2g and
h). GLUT1 was detected in immune cells within the
mammary lymph node from the NIC-GLUT1F/F
mouse (Fig. 2h, inset). Histologically, all tumors arising
in the NIC mice were consistent with those previously
described in this model and in the MMTV-Neu mam-
mary tumor model (Fig. 2c, f, and i) [32]. The resolution
of immunostaining is not sufficient to determine the ex-
tent of GLUT1 staining in the plasma membrane versus
the cytoplasm of tumor cells, although it does appear
that some GLUT1 may be cytosolic. Together, these data
suggest that GLUT1 is required for the early stages of
Neu-induced mammary tumorigenesis, and that loss of
only a single copy of Slc2a1 is sufficient to prevent the
majority of Neu-induced mammary tumors.
Reduced mammary epithelial cell proliferation in the
absence of GLUT1
We evaluated Ki67 staining in tumors from NIC-GLUT1
+/+ mice, and in mammary glands from NIC-GLUT1+/+,
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NIC-GLUT1F/+, and NIC-GLUT1F/F mice to determine
whether the differences in mammary gland morphology
observed between genotypes were due to changes in
proliferation. Tumors had the highest levels of Ki67-
positive cells (~44%) when compared to the normal
mammary epithelium from all mice (Fig. 3a and b). The
normal mammary epithelium from NIC-GLUT1F/+ and
NIC-GLUT1F/F mice had lower levels of Ki67-positive
cells compared to NIC-GLUT1+/+ mice (~6.5% and 2.3%
versus 24%, respectively; Fig. 3a, c–e). Ki67 levels in
wild-type, non-transgenic FVB control mice were
approximately 6.2% (Fig. 3a), similar to NIC-GLUT1F/+
mice, indicating that loss of both Slc2a1 alleles reduces
normal mammary epithelial proliferation below that of
wild-type mice. Overall, levels of the apoptotic marker,
cleaved Caspase-3, were very low (<0.5% of mammary
epithelial cell population) and were not different
between groups (data not shown). These data suggest
that a reduction in cell proliferation within the
mammary epithelial compartment likely contributes to
the observed differences in mammary gland structures
with reduced or absent GLUT1.
GLUT1 levels increase in early cancer cells and decrease
as mammary tumors progress
Our previous study showed that shRNA knockdown or
Cre-mediated excision of Slc2a1 from cells that had pre-
viously grown as tumors in vivo only resulted in a partial
inhibition of tumor growth [31]. This is in contrast to
the near absolute requirement for Slc2a1 in mammary
Fig. 1 Loss of GLUT1 prevents HER2/ERBB2/Neu-induced mammary tumor development. a Kaplan-Meier curve of tumor-free survival in MMTV-NIC
mice with wild-type GLUT1 (Glut1+/+), one floxed GLUT1 allele (Glut1F/+) or two floxed GLUT1 alleles (Glut1F/F). N = 17, 8, and 13 mice per group,
respectively, for GLUT1+/+, GLUT1F/+, and GLUT1F/F. Vertical marks on the curves for NIC-GLUTF/F and NIC-GLUTF/+ indicate times at which animals were
sacrificed for analysis (censored subjects). Whole mounted mammary glands (b–e) from NIC-GLUT1F/+ (b, d) and NIC-GLUT1F/F (c, e) nulliparous adult
female mice. Images b and c were captured at 4× magnification, and images d and e were captured at 10× magnification. H&E-stained sections of
mammary glands from NIC-GLUT1F/+ (f), NIC-GLUT1F/F (g), wild-type FVB (h), and NIC-GLUT1+/+ (i) nulliparous adult female mice. Scale bars for H&E
images are 300 μm
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tumorigenesis that we observed in this study (Fig. 1a).
To determine whether GLUT1 changed during tumor
growth, we examined GLUT1 protein levels in tumors of
various sizes from NIC-GLUT1+/+ mice. Immunohisto-
chemical analysis of GLUT1 levels in relation to tumor
area showed a significant inverse correlation (r = –0.67;
p < 0.0001) between tumor size and the percent of
GLUT1-positive cells (Fig. 4a). Small tumors (<2 mm2)
had more GLUT1-positive cells than larger tumors
(Fig. 4b and c), suggesting that glucose uptake is
required early during tumor formation, but that the
tumor may become less dependent on GLUT1, and
potentially on glucose, as it grows. Consistent with this,
cells from small (non-palpable) masses with strong
nuclear Cre expression showed elevation of GLUT1
(Fig. 4d and e). The observation that GLUT1 is elevated
even in very small, non-palpable tumors indicates that
GLUT1 upregulation may occur in response to onco-
gene activation and not necessarily in response to tumor
hypoxia.
To extend these observations to human breast tumors,
we evaluated SLC2A1 expression in the normal breast,
DCIS, and IDC samples from a publicly available gene
expression dataset. SLC2A1 expression was elevated in
DCIS compared to normal breast samples, although the
latter group contained only three samples. In contrast,
SLC2A1 expression was modestly but significantly re-
duced in IDC compared to DCIS tissues. This is consist-
ent with an early requirement for GLUT1 that may
decrease as breast tumors progress (Fig. 4f ).
Loss of GLUT1 influences mammary epithelial cell
composition
The dramatic reduction in mammary tumors seen with
loss of GLUT1 suggested that the population of cells in
which the NIC transgene is expressed may be eliminated
from the mammary gland as the epithelium expands.
We used immunohistochemical analysis to determine
whether mammary glands from NIC-GLUT1F/+ and
NIC-GLUT1F/F mice expressed similar levels of Cre and
GLUT1 as those from NIC-GLUT1+/+ mice. To our sur-
prise, mammary glands from NIC-GLUT1F/+ and NIC-
GLUT1F/F mice had almost no cells with strong nuclear
Cre expression (Fig. 5a). In NIC-GLUT1+/+ mammary
glands, we saw strong nuclear Cre staining (Fig. 5a).
In mammary glands from NIC-GLUT1F/+ and NIC-
Fig. 2 Cre and GLUT1 expression in tumors from NIC mice with and without GLUT1. Representative images of a tumor from a NIC-GLUT1+/+
mouse showing Cre staining (a), GLUT1 staining (b), and hematoxylin and eosin (H&E) staining (c). Representative image of a tumor from a
NIC-GLUT1F/+ mouse showing Cre staining (d), GLUT1 staining (e), and H&E staining (f). Representative image of a tumor from a NIC-GLUT1F/F
mouse showing Cre staining (g), GLUT1 staining (h), and H&E staining (i). Inset in h shows GLUT1-positive cells within the lymph node from the
same section containing the GLUT1-negative tumor
Wellberg et al. Breast Cancer Research  (2016) 18:131 Page 6 of 15
GLUT1F/F mice, we detected almost no cells with Cre
recombinase localized to the nucleus (Fig. 5b, c, and e).
As a control, we performed immunohistochemical ana-
lysis of Cre in wild-type FVB mammary glands (Fig. 5d)
and in mammary glands from NIC-negative, GLUT1
transgenic littermates (GLUT1F/+ and GLUT1F/F; data
not shown) and observed no nuclear Cre staining in any
of these groups. These data suggest that cells expressing
strong nuclear Cre (i.e., Cre capable of excising the
Slc2a1 alleles) may be eliminated from the mammary
epithelium, potentially once the Neu oncogene is
induced, and GLUT1 is excised.
Fig. 3 Reduced proliferation in mammary epithelium of mice lacking GLUT1. a Quantification of percent Ki67-positive epithelial cells in tumor tissue
and in non-tumor-bearing mammary glands. Ki67 levels were significantly lower in NIC-GLUT1F/+ and NIC-GLUT1F/F compared to NIC-GLUT1+/+
mammary epithelium. Groups with the same letter (a, b) are significantly different from each other, p < 0.05 by Mann-Whitney test. Ki67 levels in
tumors and in mammary epithelium from wild-type (WT) FVB are shown for reference. Representative images of Ki67-stained tissue from a NIC-Glut1
+/+ tumor (b) and non-tumor-bearing gland (c), and non-tumor-bearing glands from NIC-Glut1F/+ (d) and NIC-Glut1F/F (e) mice. Scale bars for images
are 200 μm
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The hierarchy of mammary stem cells has been well
characterized (reviewed in [36]). Cells expressing CD24,
with low levels of CD29 (CD24+CD29lo) are thought to
comprise the mature luminal cell type, while the CD24
+CD29hi population contains mammary stem cells. The
surface marker CD61 (β1-integrin) is expressed in ductal
or alveolar progenitor cells, and is lost as these cells ma-
ture [36]. We used flow-activated cell sorting (FACS)
analysis to identify changes in mammary epithelial cell
populations in NIC-GLUT1 transgenic mice and in
wild-type FVB mice, using CD24, CD29, and CD61.
Overall, we did not identify significant differences result-
ing from GLUT1 loss in CD24+/CD29hi cells (Fig. 5f ),
nor did we detect significant differences in the luminal
progenitor CD24+/CD29lo/CD61+ population (Fig. 5g).
The MMTV promoter is reported to be expressed in
luminal progenitor cells [37]; however, we did not see a
depletion of this cell type consistent with it being elimi-
nated from the gland.
GLUT1 inhibition or glucose restriction blocks ErbB2-
induced proliferation in vitro
To provide an in vitro correlate for the initial stages of
tumorigenesis, we used the MCF10A-ERBB2 human
breast epithelial cell line, which other investigators have
used as a model to study the early events leading to
transformation. In these cells, ERBB2 can be activated
by addition of a chemical dimerizer to the culture media,
leading to cellular transformation [34, 38]. When grown
in three-dimensional (3D) cultures in the absence of the
dimerizer, MCF10A-ERBB2 cells form hollow acinar
structures that display apical/basal polarity [38, 39].
After ERBB2 dimerization is induced, the cells begin to
proliferate and form multi-lobular structures that are
not hollow and invade the surrounding matrix [34, 38,
39]. One hallmark of ERBB2 activation in this model is
the formation of large acinar structures; thus, we deter-
mined the effect of GLUT1 inhibition, or glucose restric-
tion, on 3D acinar growth in response to ERBB2
dimerization. The standard conditions for MCF10A cell
growth use media containing 17.5 mM glucose [34, 38].
Activation of ERBB2 under these conditions significantly
increased acinar size (Fig. 6a, c, and d; compare struc-
tures in 17.5 mM glucose treated with BB to untreated).
To determine the effects of glucose restriction upon
growth of MCF10-ERBB2 cells in 3D culture, cells were
either treated with the GLUT1 inhibitor WZB117 [40],
or the media was replaced with that containing 2.5 mM
glucose at the time the “BB” dimer was added to the cul-
tures. We did not observe an effect of BB dimer with or
without WZB117 on expression of SLC2A1; however,
glucose restriction (2.5 mM) increased SLC2A1 expres-
sion in the presence of BB dimer (Fig. 6b), although
these differences did not reach significance. Both
GLUT1 inhibition and glucose restriction prevented the
formation of large acinar structures in response to
ERBB2 activation (Fig. 6a, e, and f). Analysis of BrdU
incorporation revealed that activation of ERBB2 signifi-
cantly increased cell proliferation in media containing
17.5 mM glucose (Fig. 7a–c). WZB117 addition mod-
estly but significantly decreased cell proliferation in the
presence of high glucose (Fig. 7a and d). The most
Fig. 4 GLUT1 expression decreases with increasing tumor size. a GLUT1 protein levels are inversely correlated with tumor size. Spearman correlation
r = –0.67; p < 0.0001; N = 81 tumors. Representative images of GLUT1 staining in small (b) and large (c) mammary tumors from NIC-GLUT1+/+ mice.
Scale bars in images are 200 μm. Immunohistochemistry of Cre (d) and GLUT1 (e) expression in a small, non-palpable lesion in serial sections from a
NIC-GLUT1+/+ mouse. f Analysis of SLC2A1 expression in normal breast tissue (Normal), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma
(IDC) reported in GSE59246. Groups with the same letter (a, b) are significantly different from each other, p < 0.05 by unpaired t tests
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dramatic reduction in cell proliferation was seen with
glucose restriction to 2.5 mM (Fig. 7a and e). These data
indicate that inhibition of GLUT1 or glucose restriction
inhibits cell proliferation and de-regulates growth stimu-
lated by active ERBB2.
Discussion
In this study we have demonstrated that GLUT1 is
required for tumor formation in a mouse model of
Neu-induced mammary tumorigenesis. While it has
been long appreciated that GLUT1 is overexpressed in
mammary tumors, it is unclear when expression in-
creases relative to normal breast. It has been suggested
that GLUT1 levels increase with tumor size and reflect
tumor hypoxia [41]. In addition, activated oncogenes
such as Src, ERBB2, Akt, Ras, and Myc can drive expres-
sion of GLUT1 even under normoxic conditions. In our
examination of the early preneoplastic lesions from
NIC-GLUT1+/+ mice, GLUT1 levels were high in almost
all cells and these cells also expressed Cre recombinase,
which we used as a surrogate for expression of the Neu
transgene (Fig. 4). As tumor size increased, GLUT1
Fig. 5 Nuclear Cre recombinase is not expressed in normal mammary epithelium of mice lacking GLUT1. Representative images of Cre staining
from NIC-GLUT1+/+ (a), NIC-GLUT1F/+ (b), NIC-GLUT1F/F (c), and wild-type FVB (d) mice. Inset in d is a wild-type FVB gland no-primary control.
Scale bars for images are 100 μm. e Quantification of percent cells positive for nuclear Cre recombinase (Cre) in non-tumor-bearing mammary
glands. Groups with the same letter (a, b) are significantly different from each other, p < 0.05 by Mann-Whitney tests. N = 4 mice per group. FACS
analysis of mammary cell populations Lin-CD24+CD29hi (f) and Lin-CD24+CD29loCD61+ (g) from wild-type (WT) FVB (N = 7), NIC-GLUT1+/+ (N = 4),
NIC-GLUT1F/+ (N = 4), and NIC-GLUT1F/F (N = 4) mice
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levels decreased, with approximately 30% of tumor cells
expressing high amounts of GLUT1 based on immuno-
histochemistry. Changes in SLC2A1 expression from
human tissues are similar; DCIS expressed higher
SLC2A1 than the normal breast, but levels were lower in
IDC lesions (Fig. 4). These data are consistent with our
previous work, which demonstrated that Slc2a1 knock-
down or Cre-mediated excision from mammary tumor
cell lines that had grown as tumors in vivo only reduced
tumor growth by 50% [31]. Conversely, when Slc2a1 was
excised from PyMT-transformed mammary epithelial
cells prior to orthotopic xenograft injection, no tumors
formed [31]. The decreased expression of GLUT1 in
larger tumors suggests that the requirement for GLUT1
and glucose may change as the tumor progresses;
however, the continued use of PET scanning demon-
strates that glucose is still utilized by advanced tumors.
In this study, we found that loss of a single copy of
Slc2a1 is sufficient to prevent tumorigenesis (Fig. 1). A
growing number of studies have been reported using the
NIC mice and none have observed haplo-insufficiency
for genes required for Neu-induced mammary tumori-
genesis. Genes examined for their role in ERBB2-
mediated mammary tumorigenesis include ShcA [32],
β-catenin [42], Bcl3 [43], hexokinase II [44], DOCK1
[45], LKB1 [46], 14-3-3σ [47], STAT1 [48], and specific
Fig. 6 GLUT1 inhibition or glucose restriction prevents ERBB2-induced acinar growth. a Volumes (μm) of acinar structures grown in 17.5 mM
or 2.5 mM glucose, with and without WZB117. Groups with the same letter (a, b, c) are significantly different from each other, p < 0.05 by
Mann-Whitney tests. b Quantitative PCR analysis of SLC2A1 in 3D acinar cultures under various treatments. Gene expression was normalized to
ACTB (actin). Representative images, taken 13 days after seeding, of acinar structures grown in 17.5 mM glucose without BB homodimerizer to
activate ERBB2 (c), with BB homodimerizer, added at day 6 of culture, in 17.5 mM glucose (d), with BB homodimerizer and 15 μM WZB117 added
at day 6 of culture, in 17.5 mM media (e), or with BB homodimerizer added and switched to 2.5 mM glucose at day 6 of culture (f). Scale bars in
images are 100 μm
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isoforms of phosphatidylinositol 3’-kinase [49]. The
haplo-insufficiency observed in our study indicates a
strong requirement for GLUT1 and glucose in mam-
mary tumorigenesis. This may not be surprising given
the nature of GLUT1 deficiency syndrome (GLUT1-DS),
an autosomal dominant haplo-insufficiency disorder that
results from decreased glucose transport to the brain
[50]. Patients with GLUT1-DS display motor and devel-
opmental delays, infantile onset of drug-resistant
seizures, and deceleration of head growth resulting in
acquired microcephaly, ataxia, and dystonia, [50].
Patients have decreased glucose levels in cerebrospinal
fluid with normal blood glucose levels. Our studies
would suggest that GLUT1-DS patients may be naturally
resistant to many types of cancer.
In our model, one NIC-GLUT1F/+ and one
NIC-GLUT1F/F mouse developed mammary tumors.
The tumors from the NIC-GLUT1F/+ mouse expressed
Fig. 7 GLUT1 inhibition or glucose restriction reduces cell proliferation in 3D acinar structures. a Quantification of percent BrdU-positive cells in
3D acinar structures grown in 17.5 mM or 2.5 mM glucose, with and without WZB117. Groups with the same letter (a, b, c) are significantly
different from each other, p < 0.05 by Mann-Whitney tests. Representative images, taken 8 days after seeding, of acinar structures grown in
17.5 mM glucose without BB homodimerizer to activate ERBB2 (b), with BB homodimerizer, added at day 6 of culture, in 17.5 mM glucose (c),
with BB homodimerizer and 15 μM WZB117 added at day 6 of culture, in 17.5 mM media (d), or with BB homodimerizer added and switched to
2.5 mM glucose at day 6 of culture (e). Scale bars in images are 100 μm
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Cre and GLUT1 (Fig. 2), suggesting that, in this mouse,
Slc2a1 haplo-insufficiency did not occur, and that there
may have been early changes in tumor metabolism that
overcame the loss of one Slc2a1 allele. Interestingly, all of
the tumors from the NIC-GLUT1F/F mouse expressed
nuclear Cre; however, none expressed GLUT1. The
tumors in this mouse may harbor mutations in meta-
bolic genes that allow progression in the absence of
GLUT1. Our future studies will address the possibility of
a compensatory increase in other glucose transporters as
well as potential novel mutations in metabolic genes that
allow tumors to emerge without upregulating GLUT1.
Strong nuclear Cre expression was not observed in
non-tumor-bearing mammary glands from NIC-
GLUT1F/+ or NIC-GLUT1F/F mice (Fig. 5). This suggests
that, once the HER2/ERBB2/Neu oncogene is expressed,
the requirement for GLUT1 may not be met even with
the loss of one allele. These cells may die, or may
undergo senescence and be overgrown by other cell
types in the mammary epithelium. We attempted to
identify differences in the luminal cell populations
within these mammary glands using FACS analysis; how-
ever, we were unable to demonstrate a reduction in the
luminal progenitor cell population. It is possible that the
targets of transformation in MMTV-NIC mice are indi-
cated by alternative cell markers than those we
evaluated.
To extend our in vivo observations, we examined the
effects of GLUT1 inhibition or glucose restriction on ac-
inar size in ERBB2-overexpressing MCF10A cells (Fig. 6).
The MCF10A-ERBB2 cell line is well characterized and
forms structures reminiscent of normal mammary
epithelial structures when grown in a 3D matrix. After
ERBB2 dimerization is induced, these structures prolifer-
ate and invade, much like breast cancer lesions in
patients [39]. Inhibition of GLUT1 using a small
molecule inhibitor or glucose restriction in the culture
media suppressed ERBB2-induced transformation of
MCF10A cells, measured by increased acinar size. This
suggests that it is a decrease in glucose entering tumor
cells, rather than the presence of GLUT1 itself, that sup-
presses tumorigenesis. These results are consistent with
those reported in the HMT-3522 breast cell lines. This
series includes non-malignant (S1) and malignant (T4-2)
breast cells derived from a single reduction mammo-
plasty. In this model, GLUT1 levels were not different
between S1 and T4-2 cells, but GLUT3 increased dra-
matically in malignant compared to benign cells [51]. In
addition, GLUT3 inhibition as well as glucose restriction
prevented the formation of proliferative, non-polarized
acinar structures [51]. Together, our data from
MCF10A-ERBB2 cells and the previously published
study performed on HMT-3522 cells implicate a role for
glucose in the process of breast epithelial transformation
and underscore the importance of elucidating how
cancer cell metabolism changes during tumor progres-
sion to develop optimal therapies.
The utility of targeting GLUT1 in the treatment of
cancer has been explored by other investigators. Rastogi
et al. demonstrated that treatment of two established
breast cancer cell lines, MCF7 and T47D, with anti-
GLUT1 antibody in vitro caused up to a 75% reduction
in proliferation [52]. Antisense RNA targeting GLUT5
has proved effective against two breast cancer cells lines
expressing this transporter [53]. Small molecule inhibi-
tors specific for GLUT1, including WZB117 which we
have utilized in our studies, have been identified [54], as
have inhibitors for other transporters such as GLUT5
[55]. These molecules offer the opportunity to selectively
target specific transporters as part of single or combin-
ation therapies.
Clearly our studies have utilized a single mouse model,
although it does express an oncogene that is relevant to
human breast cancer. We will extend these studies to
other mouse models of mammary tumorigenesis
dependent upon other oncogenes or tumor suppressor
genes. In addition, we are interested in determining
whether mouse models of other types of cancer (e.g.,
lung, head, and neck) are also dependent upon GLUT1.
There is an abundance of literature on cancer cell me-
tabolism reporting that tumor cells are similarly addicted
to glutamine, and that glutamine can replace glucose to
meet the bioenergetic and biosynthetic needs during cell
growth [56–62]. Many of these studies were conducted
using established cell lines that have been in culture for
years, if not decades, and heavy-atom nutrient tracers to
follow glutamine utilization. While these studies are in-
formative, it is possible that primary tumor cells in vivo
have different metabolic requirements than established
cell lines. Indeed, it was recently reported that
Ras-driven non-small-cell lung cancer displays marked
differences in metabolism when grown as orthotopic
xenografts as compared to two-dimensional culture [63].
Specifically, cells grown in vitro utilized glucose and glu-
tamine for carbon building blocks, while cells grown in
vivo appeared to rely almost exclusively on glucose [63].
Moreover, none of the studies on glutamine address
whether it can meet the metabolic needs of the cells
during the initial stages of tumorigenesis. Our study sug-
gests that, in the absence of GLUT1 and glucose uptake,
early transformed cells may not be able to use glutamine
to meet their proliferative demands. Cells within a newly
formed tumor may be metabolically inflexible, and the
ability to use other carbon sources may change as the
tumor progresses in the host environment. This would
suggest that a preventive strategy could be taken focused
entirely on modulating glucose uptake and metabolism at
the earliest stages of tumorigenesis.
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In conclusion, our data clearly indicate an important
and unique role for the GLUT1 transporter, and by
extension glucose, in the earliest stages of Neu-induced
mammary tumorigenesis in vivo, which cannot be re-
placed by other transporters or carbon sources. Despite
our increased understanding of various carbon sources
and biochemical pathways that can contribute to the
altered metabolism observed in tumor cells, it appears
that glucose metabolism remains central to the begin-
nings of tumor development. These other pathways and
carbon sources may become increasingly important as
tumors evolve; however, glucose appears to be uniquely
important in the initial stages of tumorigenesis. Further-
more, this unique role for glucose suggests the potential
for chemoprevention strategies that restrict available
glucose or block tumor glucose uptake.
Conclusions
Altered tumor cell metabolism has emerged as a
hallmark of cancer [59]. Many studies have identified
novel metabolic networks and substrates that support
the proliferation of established cancer cells in culture.
Our data show, in a conditional mouse model, that the
glucose transporter GLUT1 is required for the formation
of mammary tumors and for robust ERBB2-induced pro-
liferation in a 3D model of malignant transformation.
This study indicates that early tumor cells have not ac-
quired the ability to utilize alternative substrates for
growth, and highlights the potential to focus on glucose
restriction as a preventive strategy for breast cancer.
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